NCT06749418RecruitingEarly phase 1
Vascular Effects of High-Salt After Preeclampsia
Role of the Mineralocorticoid Receptor in Microvascular Endothelial Dysfunction After Preeclampsia
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear. The purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function. In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 19 Dec 2024
- Start date
- 2 Jan 2025
- Primary completion date
- 15 Jan 2027
- Lead sponsor
- Anna Stanhewicz, PhD
- NCT number
- NCT06749418
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 40
- From 2 Jan 2025 to the primary completion date, 15 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- current antihypertensive medication
- statin or other cholesterol-lowering medication
Other illness
- history of hypertension or metabolic disease before pregnancy
- history of gestational diabetes
- history of gestational hypertension without preeclampsia
- skin diseases
- allergy to materials used during the experiment.(e.g. latex),
- known allergy to study drugs or salt-supplement
Other
- current tobacco use
- currently pregnant
- body mass index less than 18.5 kg/m2
Who the study is looking for
- women who had preeclampsia and women who did not have preeclampsia
- 12 weeks to 5 years postpartum
- 18-45 years old
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Iowa Coordinator of this site? Confirm its status | Iowa City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.